ArticleBMC microbiology2025
Isoliquiritigenin targets las, rhl, and Pqs quorum sensing systems to mitigate the virulence and infection of Pseudomonas aeruginosa.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa.Infection · 2026Review
- Correlation between the expression of the lasR quorum‑sensing gene, biofilm‑related genes, and exotoxin A in Pseudomonas aeruginosa isolates: a Rep-PCR-based fingerprinting analysis.Molecular biology reports · 2026Article
- Quorum sensing inhibition strategies for the control of Pseudomonas aeruginosa infections.World journal of microbiology & biotechnology · 2026Review
- The bacteriophage-encoded regulator PemR attenuatesJournal of virology · 2026Article
- Multiple virulence attenuating strategies against Pseudomonas aeruginosa: Natural, synthetic, and synergistic approaches.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen with high antibiotic resistance, often causing hard-to-treat infections. Its quorum sensing (QS) system regulates virulence and drug resistance. Targeting quorum sensing via QS inhibitors is a promising strategy to combat such infections. In this study, isoliquiritigenin, a natural chalcone compound, could inhibit QS-related gene expression (lasR, lasI, rhlR, rhlI, pqsA, pqsR, lasA, rhlA, phzA1) and reduced virulence factor production of Pseudomonas aeruginosa PAO1, including protease, elastase, pyocyanin, rhamnolipid, biofilm formation and motility at subinhibitory concentrations of 50 and 100 µg/mL. The pathogenicity of PAO1 could be also attenuated by isoliquiritigenin at the tested concentrations evidenced by in vitro and vivo infection analysis via Chinese cabbage, Drosophila melanogaster, and Caenorhabditis elegans modles. Isoliquiritigenin might exhibit QSI property by targeting the las, rhl, and pqs systems based on the molecular docking analysis and the infection analysis in mutants. As a novel QSI, isoliquiritigenin develop less tendency drug resistance to PAO1, at least during the 20 generations tested. Moreover, isoliquiritigenin could increase the sensitivity of P. aeruginosa to aminoglycosides of kanamycin, amikacin or tobramycin, enhancing P. aeruginosa infection treatment. Therefore, isoliquiritigenin could function as a potential QSI against P. aeruginosa infection, either separately or synergistically combined with aminoglycosides antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.